Log in
Enquire now
‌

US Patent 10251945 Anti-ICOS agonist antibodies and uses thereof

Patent 10251945 was granted and assigned to Bristol-Myers Squibb on April, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Patent abstractTimelineTable: Further ResourcesReferences
Is a
Patent
Patent

Patent attributes

Patent Applicant
Bristol-Myers Squibb
Bristol-Myers Squibb
Current Assignee
Bristol-Myers Squibb
Bristol-Myers Squibb
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10251945
Patent Inventor Names
Mark J. Selby13
Alan J. Korman13
Brenda L. Stevens13
John J. Engelhardt13
Mary Diane Feingersh13
Date of Patent
April 9, 2019
Patent Application Number
16198387
Date Filed
November 21, 2018
Patent Citations Received
‌
US Patent 11981715 Tissue targeted immunotolerance with a CD39 effector
1
‌
US Patent 10676516 Targeted immunotolerance
2
‌
US Patent 10898556 Anti-ICOS agonist antibodies and uses thereof
3
‌
US Patent 10946068 IL-2 muteins and uses thereof
4
‌
US Patent 10961310 Targeted immunotolerance
‌
US Patent 11779632 IL-2 muteins and uses thereof
‌
US Patent 11945852 IL-2 muteins and uses thereof
7
‌
US Patent 11965008 IL-2 muteins and uses thereof
8
...
Patent Primary Examiner
‌
Ilia I Ouspenski
Patent abstract

The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer. Accordingly, the antibodies can be used in therapeutic applications and methods to detect ICOS protein.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10251945 Anti-ICOS agonist antibodies and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.